Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Receivables (2016 - 2025)

Cryo Cell International (CCEL) has disclosed Receivables for 16 consecutive years, with $7.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables fell 4.74% to $7.7 million in Q4 2025 year-over-year; TTM through Nov 2025 was $7.7 million, a 4.74% decrease, with the full-year FY2025 number at $7.7 million, down 4.74% from a year prior.
  • Receivables was $7.7 million for Q4 2025 at Cryo Cell International, roughly flat from $7.7 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $8.1 million in Q4 2024 to a low of $5.7 million in Q1 2022.
  • A 5-year average of $6.9 million and a median of $7.2 million in 2023 define the central range for Receivables.
  • Peak YoY movement for Receivables: dropped 14.74% in 2021, then rose 28.19% in 2023.
  • Cryo Cell International's Receivables stood at $5.8 million in 2021, then rose by 15.04% to $6.7 million in 2022, then rose by 9.2% to $7.3 million in 2023, then rose by 11.17% to $8.1 million in 2024, then dropped by 4.74% to $7.7 million in 2025.
  • Per Business Quant, the three most recent readings for CCEL's Receivables are $7.7 million (Q4 2025), $7.7 million (Q3 2025), and $7.7 million (Q2 2025).